SG11202105566TA - Immune activating multispecific antigen-binding molecules and uses thereof - Google Patents

Immune activating multispecific antigen-binding molecules and uses thereof

Info

Publication number
SG11202105566TA
SG11202105566TA SG11202105566TA SG11202105566TA SG11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA
Authority
SG
Singapore
Prior art keywords
binding molecules
multispecific antigen
immune activating
immune
activating
Prior art date
Application number
SG11202105566TA
Other languages
English (en)
Inventor
Sotaro Naoi
Shu Feng
Siok Wan Gan
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202105566TA publication Critical patent/SG11202105566TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202105566TA 2020-03-31 2021-03-30 Immune activating multispecific antigen-binding molecules and uses thereof SG11202105566TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062357 2020-03-31
PCT/JP2021/013456 WO2021200896A1 (en) 2020-03-31 2021-03-30 Immune activating multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11202105566TA true SG11202105566TA (en) 2021-11-29

Family

ID=77928944

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105566TA SG11202105566TA (en) 2020-03-31 2021-03-30 Immune activating multispecific antigen-binding molecules and uses thereof

Country Status (9)

Country Link
US (1) US20230147840A1 (enrdf_load_stackoverflow)
EP (1) EP4126958A4 (enrdf_load_stackoverflow)
JP (1) JP2021175391A (enrdf_load_stackoverflow)
KR (1) KR20220161156A (enrdf_load_stackoverflow)
CN (1) CN115315447A (enrdf_load_stackoverflow)
AR (1) AR121692A1 (enrdf_load_stackoverflow)
SG (1) SG11202105566TA (enrdf_load_stackoverflow)
TW (1) TW202204410A (enrdf_load_stackoverflow)
WO (1) WO2021200896A1 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3070168T3 (pl) 2013-11-11 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zawierająca zmodyfikowany region zmienny przeciwciała
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
CN112533943B (zh) * 2018-06-01 2024-03-05 利兰斯坦福初级大学董事会 Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
WO2025109518A1 (en) * 2023-11-21 2025-05-30 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279512A3 (en) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11952422B2 (en) * 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
CA3114154A1 (en) * 2018-09-28 2020-04-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
MX2021003609A (es) * 2018-09-28 2021-05-28 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que comprende una region variable de anticuerpo alterada.

Also Published As

Publication number Publication date
AR121692A1 (es) 2022-06-29
WO2021200896A1 (en) 2021-10-07
EP4126958A1 (en) 2023-02-08
TW202204410A (zh) 2022-02-01
JP2021175391A (ja) 2021-11-04
KR20220161156A (ko) 2022-12-06
EP4126958A4 (en) 2024-07-24
US20230147840A1 (en) 2023-05-11
CN115315447A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
SG11202105566TA (en) Immune activating multispecific antigen-binding molecules and uses thereof
SG11202105302PA (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
IL287848A (en) Multispecific antigen binding molecules and their uses
PT3818086T (pt) Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3
SG11202100935TA (en) Collagen-localized immunomodulatory molecules and methods thereof
SG11202104264TA (en) Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
PL3518972T3 (pl) Cząsteczki wiążące antygen i sposoby ich zastosowania
EP3826667A4 (en) ANTIBODIES TO CLAUDIN 6 AND METHODS OF TREATING CANCER
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
IL315265A (en) Multiple antibodies and their uses
GB201503812D0 (en) Antibody molecules and uses thereof
PL3484488T3 (pl) Cząsteczki wiążące antygeny i sposoby ich stosowania
IL278832A (en) Improved molecules that bind 41GP
IL321951A (en) Multispecific antibodies and their uses
EP3245204A4 (en) Small molecules for the treatment of primary cancer and cancer metastasis
IL311096A (en) Antigen binding molecules and their uses
GB201621591D0 (en) Antibody molecules and method
IL315541A (en) Multispecific antibodies and their uses
IL315540A (en) Multispecific antibodies and their uses
IL285585A (en) fcmr-binding molecules and their uses
ZA201904626B (en) Cancer treatment method and composition
IL317637A (en) Anti-STEAP1 antigen binding molecules and their uses
IL315544A (en) Multispecific antibodies and their uses
HK40102075A (en) Antigen binding molecules and methods of use thereof
HK40112679A (en) Antigen-binding molecules and uses thereof